Randomized Clinical Trial
Copyright ©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5986-5993
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5986
Table 2 Results of bowel cleansing and adverse effects
Group A (fixed time split dose preparation) n = 99Group B (split dose preparation) n = 105P value
Mean total Ottawa preparation score12.57 ± 1.912.80 ± 2.510.457
Age ≥ 653.40 ± 2.033.38 ± 2.980.976
Right colon, mean (0-4)0.92 ± 0.710.96 ± 0.820.692
Mid colon, mean (0-4)0.76 ± 0.740.76 ± 0.830.969
Rectosigmoid colon, mean (0-4)0.73 ± 0.680.74 ± 0.850.886
Residual fluid, mean (0-2)0.17 ± 0.430.33 ± 0.560.023
Adverse GI symptoms, n (%)
Nausea21 (21.2)14 (13.3)0.136
Vomiting7 (7.1)3 (2.9)0.164
Sleep disturbance2 (2)0 (0)0.143
Abdominal discomfort7 (7.1)5 (4.8)0.484
Dizziness1 (1)5 (4.8)0.113
Cold sweating1 (1)0 (0)0.302
Palpitation0 (0)1 (1)0.330
Mean cecal intubation time, min ± SD5.02 ± 3.424.70 ± 2.270.428
Physician's satisfaction of inspection8.17 ± 1.218.04 ± 1.510.489